Stock Analiz

GeneDx Holdings Corp. (WGS) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

GeneDx Holdings’s revenue went from $196M in fiscal 2019 to $428M in fiscal 2025, growth of about 13.9% a year.

Net income in fiscal 2025 was -$21M, a net margin of -4.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $461M and net income -$111M.

Free cash flow was $14M in fiscal 2025 and positive in 1 of the 7 years shown.

The diluted share count rose 762239595% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $196M20192020: $179M20202021: $212M20212022: $235M20222023: $203M20232024: $305M20242025: $428M2025$428M
Net income
2019: -$30M20192020: -$241M20202021: -$245M20212022: -$549M20222023: -$176M20232024: -$52M20242025: -$21M2025-$21M
Free cash flow
2019: -$31M20192020: -$117M20202021: -$200M20212022: -$326M20222023: -$185M20232024: -$34M20242025: $14M2025$14M
EPS (diluted)
2019: $-8713848.0020192020: $-1552188.0020202021: $-74.9120212022: $-53.6320222023: $-7.2320232024: $-1.9420242025: $-0.732025$-0.73

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$461M$428M$305M$203M$235M$212M$179M$196M
Gross profit$317M$298M$194M$90M-$27M-$17M$4M$83M
Operating income-$100M-$13M-$23M-$181M-$668M-$446M-$242M-$30M
Net income-$111M-$21M-$52M-$176M-$549M-$245M-$241M-$30M
EPS (diluted)$-3.78$-0.73$-1.94$-7.23$-53.63$-74.91$-1552188.00$-8713848.00
R&D$81M$72M$46M$58M$86M$105M$73M$35M
Revenue growth—+40.0%+50.8%−13.7%+10.6%+18.3%−8.6%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$75M$33M-$28M-$180M-$319M-$190M-$93M-$19M
Capital spending-$26M-$19M-$5M-$5M-$7M-$9M-$24M-$12M
Free cash flow-$101M$14M-$34M-$185M-$326M-$200M-$117M-$31M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$33M$32M$9M-$326000$42M$219M$120M$5M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$171M$141M$130M$124M$401M$108M$115M
Debt—$97M$101M$103M$58M$11M$21M—
Equity—$308M$245M$228M$254M$388M-$330M-$89M
Total assets—$524M$419M$419M$491M$554M$252M—
Shares (diluted)30M29M27M24M10M3M0M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin68.7%69.7%63.6%44.4%-11.4%-7.8%2.2%42.2%
Operating margin-21.6%-3.1%-7.6%-89.1%-284.5%-210.2%-134.9%-15.5%
Net margin-24.1%-4.9%-17.1%-86.8%-233.9%-115.6%-134.6%-15.1%
FCF margin-22.0%3.3%-11.1%-91.5%-139.0%-94.2%-65.4%-15.6%
ROIC—-3.2%-6.7%-54.3%-196.7%-111.8%——
ROE—-6.8%-21.3%-77.1%-216.4%-63.2%73.1%33.5%

Frequently asked questions

What is GeneDx Holdings’s annual revenue?

$428M in fiscal 2025 and $461M over the twelve months to September 30, 2026.

How much profit does GeneDx Holdings make?

Net income was -$21M in fiscal 2025 (net margin -4.9%).

Is GeneDx Holdings’s revenue growing?

Yes: revenue rose 40.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.